2906, 2020
New European recommendations on DPD testing prior to anticancer therapy with fluoropyrimidines
Last April 30th, the European Medicines Agency (EMA) published recommendations [...]
1604, 2020
A new therapeutic opportunity treatment of NSCLC: the BRAF V600 mutation
FDA and EMA approved and reimbursed dabrafenib + trametinib combination [...]